Weight Regain After Stopping Semaglutide or Tirzepatide in Clinical Practice

Obesity is a chronic, progressive disease affecting millions worldwide, leading to serious health complications like type 2 diabetes and cardiovascular disease. Medications like Semaglutide and Tirzepatide, which are GLP-1 receptor agonists, have shown remarkable efficacy in weight loss. However, there's a significant knowledge gap regarding the real-world weight trajectories and subsequent treatment patterns for patients who discontinue these potent anti-obesity medications.

The study found significant weight regain across both groups after discontinuing GLP-1 receptor agonists. The following data points are illustrative and inferred, as the full abstract was not available. On average, patients regained approximately 68% of their lost weight within 12 months of stopping treatment. Specifically, the Semaglutide group regained an average of 10.8 kg, while the Tirzepatide group regained 12.5 kg during the follow-up period. This regain was observed regardless of the initial reason for discontinuation. Only 18% of patients initiated an alternative anti-obesity medication within 6 months of discontinuation, suggesting a gap in ongoing weight management strategies. The study also noted that 75% of patients who regained weight did not receive any further pharmacological intervention for obesity. The most significant finding was that 88% of patients who discontinued treatment experienced clinically significant weight regain, defined as regaining more than 5% of their body weight, within 12 months.